Marty Makary has stepped down as FDA commissioner amid controversy, but the debate around his exit is also drawing attention to the policy changes he advanced while leading the agency. Much of that legacy centers on two themes: speeding up drug review timelines and expanding the role of artificial intelligence inside the FDA.
Those efforts are being framed as some of the most important modernization moves at the agency in decades. In practical terms, the focus was on making reviews more efficient and updating how the FDA handles its workload, especially in areas where long timelines and aging systems have often drawn criticism.
Makary’s tenure therefore leaves a mixed public picture. On one side is the controversy surrounding his resignation. On the other is a reform agenda aimed at reshaping how the FDA evaluates treatments and uses technology to manage complex regulatory tasks. That combination makes his time in office notable even beyond the circumstances of his departure.
As attention shifts to what comes next for the agency, the lasting question may be whether those changes continue. If the push for quicker drug reviews and broader AI adoption remains in place, Makary’s brief and disputed tenure could still have a long-term effect on how the FDA operates.
